DCM
CPRX

Driehaus Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Driehaus Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,230,787
Closed -$4.81M – 506
2017
Q4 		$4.81M Buy
+1,230,787
New +$4.07M 0.18% 152

Other funds holding CPRX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Driehaus Capital Management's CPRX Position: Q1 2018 in Review

Driehaus Capital Management sold out of Catalyst Pharmaceutical (CPRX) in Q1 2018, closing a stake of 1,230,787 shares — an estimated $4.81M sold.

Driehaus Capital Management first reported a position in CPRX in Q4 2017 and held it in 1 quarter. The position peaked at $4.81M in Q4 2017. 98 funds tracked by Wall St. Rank hold CPRX as of Q1 2018.

  • Driehaus Capital Management reported no remaining Catalyst Pharmaceutical position as of Q1 2018 after selling out during the quarter.
  • Driehaus Capital Management sold 1,230,787 Catalyst Pharmaceutical shares in Q1 2018, an estimated $4.81M.
  • Driehaus Capital Management first reported a position in Catalyst Pharmaceutical in Q4 2017 and held it in 1 quarter.
  • Driehaus Capital Management's Catalyst Pharmaceutical position peaked at $4.81M in Q4 2017.
  • 98 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2018.

Based on Driehaus Capital Management's 13F filing for Q1 2018, filed 15 May 2018.